IMCR Immunocore Holdings ADS

Immunocore to present at upcoming investor conferences

Immunocore to present at upcoming investor conferences

(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 8 November 2024) , a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that management will participate in the following investor conferences in November.

                  Guggenheim Securities Healthcare Innovation Conference

                  Fireside Chat: Tuesday, November 12, 2024, at 1:00 p.m. EST

                  Jefferies London Healthcare Conference

                  Fireside Chat: Wednesday, November 21, 2024, at 9:00 a.m. GMT

The presentations will be webcast live and can be accessed by visiting ‘Events & Presentations’, under ‘Events’, via the ‘Investors’ section of Immunocore’s website at Following the event, a replay of the presentations will be made available for a limited time.

About Immunocore

Immunocore is a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of diseases, including cancer, autoimmune, and infectious disease. Leveraging its proprietary, flexible, off-the-shelf ImmTAX platform, Immunocore is developing a deep pipeline in multiple therapeutic areas, including five clinical stage programs in oncology and infectious disease, advanced pre-clinical programs in autoimmune disease and multiple earlier pre-clinical programs. The Company’s most advanced oncology TCR therapeutic, KIMMTRAK has been approved for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma in the United States, European Union, Canada, Australia, and the United Kingdom.

Contact Information

Immunocore

Sébastien Desprez, Head of Communications

T: +44 (0) 7458030732

E:

Follow on Twitter: @Immunocore

Investor Relations

Clayton Robertson, Head of Investor Relations

T: +1 (215) 384-4781

E:



EN
08/11/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Immunocore Holdings ADS

 PRESS RELEASE

Immunocore announces first patient dosed in the Phase 1 trial of IMC-P...

Immunocore announces first patient dosed in the Phase 1 trial of IMC-P115C, a half-life extended (HLE) ImmTAC candidate in patients with tumors that express PRAME Immunocore announces first patient dosed in the Phase 1 trial of IMC-P115C, a half-life extended (HLE) ImmTAC candidate in patients with tumors that express PRAME IMC-P115C (PRAME-HLE-A02) targets the same peptide and has the same CD3 effector and TCR specificity as brenetafusp, and is designed with extended half-life   The Phase 1 trial will assess the safety and clinical activity of IMC-P115C in HLA-A*02:01-positive patients w...

 PRESS RELEASE

Immunocore announces treatment of first patient in the Phase 1/2 trial...

Immunocore announces treatment of first patient in the Phase 1/2 trial of IMC-R117C targeting PIWIL1 in advanced gastrointestinal cancers The Phase 1/2 trial will assess the safety and clinical activity of IMC-R117C, as a monotherapy and in combination with standards of care, in patients with advanced cancers expressing PIWIL1 First immunotherapy program to target PIWIL1, a cancer-testis antigen overexpressed in a range of cancers, including colorectal cancer (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 17 December 2024) , a commercial-stage biotechnology company pion...

 PRESS RELEASE

EORTC and Immunocore announce enrolment of first patient onto the only...

EORTC and Immunocore announce enrolment of first patient onto the only active Phase 3 adjuvant trial in uveal melanoma ATOM is the only active Phase 3 trial for adjuvant treatment of uveal melanoma The trial will assess whether adjuvant treatment with tebentafusp can decrease the risk of relapse, compared to observation (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 11 December 2024) The European Organisation for Research and Treatment of Cancer (EORTC), an independent clinical cancer research organization focusing on improving the standards of cancer treatments for pat...

 PRESS RELEASE

Immunocore announces reimbursement agreement in England for KIMMTRAK▼ ...

Immunocore announces reimbursement agreement in England for KIMMTRAK▼ for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma Immunocore announces reimbursement agreement in England for KIMMTRAK▼ for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 03 December 2024) , a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, inf...

 PRESS RELEASE

Immunocore to present at upcoming investor conferences

Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 8 November 2024) , a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that management will participate in the following investor conferences in November.                   Guggenheim Securities Healthcare Innovation Conference                   Fireside Chat: Tuesday, November 12, 2024, at 1:00...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch